NKp46 regulates the production of serine proteases and IL‐22 in human mast cells in urticaria pigmentosa. Issue 9 (26th May 2015)

• Record Type: Journal Article
• Authors: Ueshima, Chiyuki; Kataoka, Tatsuki R.; Hirata, Masahiro; Koyanagi, Itsuko; Honda, Tetsuya; Tsuruyama, Tatsuaki; Okayama, Yoshimichi; Seiyama, Akitoshi; Haga, Hironori
• Is Part Of: Experimental dermatology. Volume 24:Issue 9(2015:Sep.)
• Page Start: 675
• Page End: 679
• Publication Date: 2015-05-26
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.12741
• Languages: English
• ISSNs: 0906-6705

Abstract

<abstract abstract-type="main" id="exd12741-abs-0001"> <title>Abstract</title> <p>NKp46 (natural cytotoxic receptor 1/CD335) is expressed on natural killer cells and Th2‐type innate lymphocytes. However, NKp46 expression in human mast cells has not yet been reported. Here, we explored the expression of, and possible role played by, NKp46 in such cells. NKp46 protein was expressed in human mast cells in urticaria pigmentosa principally of the tryptase‐positive/chymase‐negative type (MCT), but not in human non‐neoplastic skin mast cells of the tryptase‐positive/chymase‐positive (MCTC) type. NKp46 expression was also evident in the human neoplastic mast cell line HMC1.2. NKp46 knockdown changed the phenotype of this cell line from MCT to MCTC and downregulated GrB production, but did not influence IL‐22 production. An agonistic anti‐NKp46 antibody upregulated production of GrB and IL‐22, but did not change the MCT‐like phenotype of HMC1.2 cells. NKp46 was thus involved in the production of serine proteases and IL‐22 in human mast cells.</p> </abstract>